<DOC>
	<DOCNO>NCT00749047</DOCNO>
	<brief_summary>Pioglitazone insulin sensitise drug use treatment patient type 2 diabetes . In addition blood sugar lower effect , pioglitazone also number beneficial effect , one reduce loss protein urine . The mechanism protein `` spar effect '' pioglitazone fully understood . The propose study investigate whether pioglitazone beneficial effect filtration characteristic filter kidney responsible retain protein body . The effect pioglitazone size pore filter also electrostatic charge barrier surround pore investigate . The clinical study involve 12 patient type 2 diabetes minimal urine protein loss , take low dose pioglitazone 3 month . Blood urine sample collect beginning , mid point end study use measure concentration specific proteins different size electrostatic charge . This data use identify characterise change filtration property kidney filter study .</brief_summary>
	<brief_title>How Does Diabetes Drug , Pioglitazone , Reduce Protein Loss Urine ?</brief_title>
	<detailed_description>In addition insulin sensitise action , thiazolidinediones ( TZDs ) beneficial effect vascular function . These include decrease proteinuria amelioration diabetic nephropathy . Although anti-proteinuric effect TZDs well establish mechanism ( ) underlying change yet determine . Possible mechanisms include altered renal haemodynamics , maintenance anionic electrostatic filtration barrier glomerular basement membrane pleiotropic effect . The target TZDs , peroxisome proliferator-activated receptor ( PPARs ) , directly modulate vessel wall function . The kidney differentially express PPAR isoforms evidence TZDs pleiotropic effect kidney metabolic haemodynamic action . These effect include direct action culture mesangial cell , inhibition vivo mesangial expansion , reduction podocyte injury , decrease production type IV collagen urinary endothelin-1 level early stage diabetic nephropathy . Glomerular ultrafiltration plasma protein govern size filtration pore extent anionic site basement membrane podocyte slit pore junction . It possible anti-proteinuric effect TZDs attributable increase size and/or charge selectivity glomerular filtration barrier . A Medline search show study effect TZDs protein ultrafiltration . The aim propose study measure urinary protein size charge selectivity patient early stage diabetic nephropathy treatment TZD , pioglitazone .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Diabetes mellitus , Type 2 Age 1870 yr Overt proteinuria ( urine albumin : creatinine ratio &gt; 10.0 Plasma creatinine 0.15 mmol/L HbA1c &gt; 10 % Hear failure Class III IV Peripheral oedema Abnormal liver function ( serum AST &gt; 2.5 time upper limit normal ) Pregnancy breastfeed History urinary tract infection Serious concomitant disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Pioglitazone</keyword>
	<keyword>Open study</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>Glomerular selectivity index</keyword>
</DOC>